Cargando…
Development and clinical application of a rapid SARS‐CoV‐2 antibody test strip: A multi‐center assessment across China
BACKGROUND: The ongoing coronavirus disease 19 (COVID‐19) is posing a threat to the public health globally. Serological test for SARS‐CoV‐2 antibody can improve early diagnosis of COVID‐19 and serves as a valuable supplement to RNA detection. METHOD: A SARS‐CoV‐2 IgG/IgM combined antibody test strip...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7645889/ https://www.ncbi.nlm.nih.gov/pubmed/33067888 http://dx.doi.org/10.1002/jcla.23619 |
_version_ | 1783606710181560320 |
---|---|
author | Liao, Mengting Yan, Jiawei Wang, Xinfeng Qian, Huimin Wang, Chao Xu, Dan Wang, Bin Yang, Bo Liu, Shaohui Zhou, Mao Gao, Qian Zhou, Qian Luo, Jiquan Li, Zongxiang Liu, Wenen |
author_facet | Liao, Mengting Yan, Jiawei Wang, Xinfeng Qian, Huimin Wang, Chao Xu, Dan Wang, Bin Yang, Bo Liu, Shaohui Zhou, Mao Gao, Qian Zhou, Qian Luo, Jiquan Li, Zongxiang Liu, Wenen |
author_sort | Liao, Mengting |
collection | PubMed |
description | BACKGROUND: The ongoing coronavirus disease 19 (COVID‐19) is posing a threat to the public health globally. Serological test for SARS‐CoV‐2 antibody can improve early diagnosis of COVID‐19 and serves as a valuable supplement to RNA detection. METHOD: A SARS‐CoV‐2 IgG/IgM combined antibody test strip based on colloidal gold immunochromatography assay was developed, with both spike protein and nucleocapsid protein of SARS‐CoV‐2 antigen used for antibody detection. From 3 medical institutions across China, serum or plasma of 170 patients with confirmed COVID‐19 diagnosis and 300 normal controls were collected and tested with the strip. Sensitivity, specificity, kappa coefficient, receiver operating characteristic (ROC) curve, and area under the curve (AUC) were analyzed. Positive rates in different medical centers, age group, gender, and different disease course were compared. RESULTS: 158 out 170 samples from confirmed COVID‐19 patients had positive results from the test, and 296 out of 300 samples from normal controls had negative results. The kit was 92.9% sensitive and 98.7% specific. The positive rate was 77.3% during the first week after disease onset, but reached 100% since day 9. AUC and kappa coefficient were 0.958 and 0.926, respectively, which showed the consistency of the test results with the standard diagnosis. Age or gender caused little variations in the kit sensitivity. CONCLUSION: The rapid, easy‐to‐use SARS‐CoV‐2 IgG/IgM combined antibody test kit has a superior performance, which can help with accurate diagnosis and thus timely treatment and isolation of COVID‐19 patients, that contributes to the better control of the global pandemic. |
format | Online Article Text |
id | pubmed-7645889 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-76458892020-11-06 Development and clinical application of a rapid SARS‐CoV‐2 antibody test strip: A multi‐center assessment across China Liao, Mengting Yan, Jiawei Wang, Xinfeng Qian, Huimin Wang, Chao Xu, Dan Wang, Bin Yang, Bo Liu, Shaohui Zhou, Mao Gao, Qian Zhou, Qian Luo, Jiquan Li, Zongxiang Liu, Wenen J Clin Lab Anal Research Articles BACKGROUND: The ongoing coronavirus disease 19 (COVID‐19) is posing a threat to the public health globally. Serological test for SARS‐CoV‐2 antibody can improve early diagnosis of COVID‐19 and serves as a valuable supplement to RNA detection. METHOD: A SARS‐CoV‐2 IgG/IgM combined antibody test strip based on colloidal gold immunochromatography assay was developed, with both spike protein and nucleocapsid protein of SARS‐CoV‐2 antigen used for antibody detection. From 3 medical institutions across China, serum or plasma of 170 patients with confirmed COVID‐19 diagnosis and 300 normal controls were collected and tested with the strip. Sensitivity, specificity, kappa coefficient, receiver operating characteristic (ROC) curve, and area under the curve (AUC) were analyzed. Positive rates in different medical centers, age group, gender, and different disease course were compared. RESULTS: 158 out 170 samples from confirmed COVID‐19 patients had positive results from the test, and 296 out of 300 samples from normal controls had negative results. The kit was 92.9% sensitive and 98.7% specific. The positive rate was 77.3% during the first week after disease onset, but reached 100% since day 9. AUC and kappa coefficient were 0.958 and 0.926, respectively, which showed the consistency of the test results with the standard diagnosis. Age or gender caused little variations in the kit sensitivity. CONCLUSION: The rapid, easy‐to‐use SARS‐CoV‐2 IgG/IgM combined antibody test kit has a superior performance, which can help with accurate diagnosis and thus timely treatment and isolation of COVID‐19 patients, that contributes to the better control of the global pandemic. John Wiley and Sons Inc. 2020-10-16 /pmc/articles/PMC7645889/ /pubmed/33067888 http://dx.doi.org/10.1002/jcla.23619 Text en © 2020 The Authors. Journal of Clinical Laboratory Analysis published by Wiley Periodicals LLC This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Articles Liao, Mengting Yan, Jiawei Wang, Xinfeng Qian, Huimin Wang, Chao Xu, Dan Wang, Bin Yang, Bo Liu, Shaohui Zhou, Mao Gao, Qian Zhou, Qian Luo, Jiquan Li, Zongxiang Liu, Wenen Development and clinical application of a rapid SARS‐CoV‐2 antibody test strip: A multi‐center assessment across China |
title | Development and clinical application of a rapid SARS‐CoV‐2 antibody test strip: A multi‐center assessment across China |
title_full | Development and clinical application of a rapid SARS‐CoV‐2 antibody test strip: A multi‐center assessment across China |
title_fullStr | Development and clinical application of a rapid SARS‐CoV‐2 antibody test strip: A multi‐center assessment across China |
title_full_unstemmed | Development and clinical application of a rapid SARS‐CoV‐2 antibody test strip: A multi‐center assessment across China |
title_short | Development and clinical application of a rapid SARS‐CoV‐2 antibody test strip: A multi‐center assessment across China |
title_sort | development and clinical application of a rapid sars‐cov‐2 antibody test strip: a multi‐center assessment across china |
topic | Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7645889/ https://www.ncbi.nlm.nih.gov/pubmed/33067888 http://dx.doi.org/10.1002/jcla.23619 |
work_keys_str_mv | AT liaomengting developmentandclinicalapplicationofarapidsarscov2antibodyteststripamulticenterassessmentacrosschina AT yanjiawei developmentandclinicalapplicationofarapidsarscov2antibodyteststripamulticenterassessmentacrosschina AT wangxinfeng developmentandclinicalapplicationofarapidsarscov2antibodyteststripamulticenterassessmentacrosschina AT qianhuimin developmentandclinicalapplicationofarapidsarscov2antibodyteststripamulticenterassessmentacrosschina AT wangchao developmentandclinicalapplicationofarapidsarscov2antibodyteststripamulticenterassessmentacrosschina AT xudan developmentandclinicalapplicationofarapidsarscov2antibodyteststripamulticenterassessmentacrosschina AT wangbin developmentandclinicalapplicationofarapidsarscov2antibodyteststripamulticenterassessmentacrosschina AT yangbo developmentandclinicalapplicationofarapidsarscov2antibodyteststripamulticenterassessmentacrosschina AT liushaohui developmentandclinicalapplicationofarapidsarscov2antibodyteststripamulticenterassessmentacrosschina AT zhoumao developmentandclinicalapplicationofarapidsarscov2antibodyteststripamulticenterassessmentacrosschina AT gaoqian developmentandclinicalapplicationofarapidsarscov2antibodyteststripamulticenterassessmentacrosschina AT zhouqian developmentandclinicalapplicationofarapidsarscov2antibodyteststripamulticenterassessmentacrosschina AT luojiquan developmentandclinicalapplicationofarapidsarscov2antibodyteststripamulticenterassessmentacrosschina AT lizongxiang developmentandclinicalapplicationofarapidsarscov2antibodyteststripamulticenterassessmentacrosschina AT liuwenen developmentandclinicalapplicationofarapidsarscov2antibodyteststripamulticenterassessmentacrosschina |